• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study)

    Author(s)
    Van Wijmeersch, B
    Barone, D
    Broadley, S
    Dive, D
    Hupperts, RMM
    Lycke, J
    Massacesi, L
    Montalban, X
    Naismith, RT
    Pandey, K
    Schippling, S
    Vermersch, P
    Chung, L
    Daizadeh, N
    et al.
    Griffith University Author(s)
    Broadley, Simon
    Year published
    2018
    Metadata
    Show full item record
    Abstract
    Aims: Evaluate efficacy and safety of alemtuzumab over 6 y in patients who initiated alemtuzumab after receiving SC IFNB-1a in CARE-MS I. Methods: At investigator discretion, patients in TOPAZ can receive additional as-needed alemtuzumab (≥12 months apart; no criteria), or receive another DMT (at any time). MRI disease activity was defined as new gadolinium (Gd)-enhancing or new/enlarging T2 hyperintense lesions. Results: Of 139 patients initiating alemtuzumab in the extension, 117 (84%) completed Y2 of TOPAZ (Y6 after initiating alemtuzumab); 67% received neither additional courses of alemtuzumab nor another DMT. At ...
    View more >
    Aims: Evaluate efficacy and safety of alemtuzumab over 6 y in patients who initiated alemtuzumab after receiving SC IFNB-1a in CARE-MS I. Methods: At investigator discretion, patients in TOPAZ can receive additional as-needed alemtuzumab (≥12 months apart; no criteria), or receive another DMT (at any time). MRI disease activity was defined as new gadolinium (Gd)-enhancing or new/enlarging T2 hyperintense lesions. Results: Of 139 patients initiating alemtuzumab in the extension, 117 (84%) completed Y2 of TOPAZ (Y6 after initiating alemtuzumab); 67% received neither additional courses of alemtuzumab nor another DMT. At Y6, the annualised relapse rate was 0.19, and 70% of patients had stable/improved EDSS scores from CARE-MS I baseline. After initiating alemtuzumab, 69% were free from 6-month confirmed disability worsening and 28% had 6-month confirmed disability improvement. At Y6, 62% were free of MRI disease activity, 82% were free of new Gd-enhancing lesions, and 62% were free of new/enlarging T2 hyperintense lesions. Median percent cumulative brain volume loss (BVL) from CARE-MS I baseline was -1.99% over 8 total study y; -1.49% occurred over Y0-2 with SC IFNB-1a, and -0.23% occurred over 6 y with alemtuzumab. Safety was consistent with the alemtuzumab arm of the core and extension studies. Conclusions: Alemtuzumab improved clinical, MRI, and BVL outcomes in patients who initiated alemtuzumab after receiving SC IFNB-1a in CARE-MS I. These improved outcomes were maintained over 6 y in the absence of continuous treatment, with a consistent safety profile that is manageable and acceptable.
    View less >
    Conference Title
    Multiple Sclerosis Journal
    Volume
    24
    Publisher URI
    https://journals.sagepub.com/doi/full/10.1177/1352458518798590
    Subject
    Clinical Sciences
    Neurosciences
    Science & Technology
    Life Sciences & Biomedicine
    Clinical Neurology
    Neurosciences
    Neurosciences & Neurology
    Publication URI
    http://hdl.handle.net/10072/403214
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander